Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|May 1, 2025
Clinically Inactive Disease and Remission in Patients with Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post-Hoc Analysis of a Phase III TrialAlessandro Consolaro, Nicolino Ruperto, Daniel J Lovell, et al.
Frontiers in Medicine|November 30, 2023
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered studyEkaterina Alexeeva, Meiri Shingarova, Tatyana Dvoryakovskaya, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 13, 2020
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized StudyPierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, et al.
The Journal of Clinical Endocrinology and Metabolism|July 6, 2021
Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 TrialLeanne M Ward, Anup Choudhury, Nathalie Alos, et al.
The Journal of Rheumatology|March 3, 2019
Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic ArthritisManuela Pardeo, Jianmei Wang, Nicolino Ruperto, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 11, 2020
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension StudyHermine I Brunner, Pierre Quartier, Ekaterina Alexeeva, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 31, 2025
Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient-Reported Outcomes in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal TrialHermine I Brunner, Ekaterina Alexeeva, Marcia Bandeira, et al.
Annals of the Rheumatic Diseases|August 12, 2022
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trialHermine I Brunner, Ivan Foeldvari, Ekaterina Alexeeva, et al.
Rheumatology (Oxford, England)|March 29, 2024
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritisHermine I Brunner, Nicolino Ruperto, Athimalaipet V Ramanan, et al.
Rheumatology (Oxford, England)|January 20, 2024
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registryDaniel J Lovell, Nikolay Tzaribachev, Michael Henrickson, et al.
Pageof 4